336 related articles for article (PubMed ID: 24572810)
1. Splicing factor hnRNP A2 activates the Ras-MAPK-ERK pathway by controlling A-Raf splicing in hepatocellular carcinoma development.
Shilo A; Ben Hur V; Denichenko P; Stein I; Pikarsky E; Rauch J; Kolch W; Zender L; Karni R
RNA; 2014 Apr; 20(4):505-15. PubMed ID: 24572810
[TBL] [Abstract][Full Text] [Related]
2. Up-regulation and subcellular localization of hnRNP A2/B1 in the development of hepatocellular carcinoma.
Cui H; Wu F; Sun Y; Fan G; Wang Q
BMC Cancer; 2010 Jul; 10():356. PubMed ID: 20604928
[TBL] [Abstract][Full Text] [Related]
3. Protein kinase C alpha trigger Ras and Raf-independent MEK/ERK activation for TPA-induced growth inhibition of human hepatoma cell HepG2.
Wen-Sheng W
Cancer Lett; 2006 Jul; 239(1):27-35. PubMed ID: 16169661
[TBL] [Abstract][Full Text] [Related]
4. c-Myc regulates RNA splicing of the A-Raf kinase and its activation of the ERK pathway.
Rauch J; Moran-Jones K; Albrecht V; Schwarzl T; Hunter K; Gires O; Kolch W
Cancer Res; 2011 Jul; 71(13):4664-74. PubMed ID: 21512137
[TBL] [Abstract][Full Text] [Related]
5. HnRNP A1/A2 and SF2/ASF regulate alternative splicing of interferon regulatory factor-3 and affect immunomodulatory functions in human non-small cell lung cancer cells.
Guo R; Li Y; Ning J; Sun D; Lin L; Liu X
PLoS One; 2013; 8(4):e62729. PubMed ID: 23658645
[TBL] [Abstract][Full Text] [Related]
6. Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.
Song CQ; Li Y; Mou H; Moore J; Park A; Pomyen Y; Hough S; Kennedy Z; Fischer A; Yin H; Anderson DG; Conte D; Zender L; Wang XW; Thorgeirsson S; Weng Z; Xue W
Gastroenterology; 2017 Apr; 152(5):1161-1173.e1. PubMed ID: 27956228
[TBL] [Abstract][Full Text] [Related]
7. RRM1 domain of the splicing oncoprotein SRSF1 is required for MEK1-MAPK-ERK activation and cellular transformation.
Shimoni-Sebag A; Lebenthal-Loinger I; Zender L; Karni R
Carcinogenesis; 2013 Nov; 34(11):2498-504. PubMed ID: 23843040
[TBL] [Abstract][Full Text] [Related]
8. Aptamer BC15 against heterogeneous nuclear ribonucleoprotein A1 has potential value in diagnosis and therapy of hepatocarcinoma.
Li S; Wang W; Ding H; Xu H; Zhao Q; Li J; Li H; Xia W; Su X; Chen Y; Fang T; Shao N; Zhang H
Nucleic Acid Ther; 2012 Dec; 22(6):391-8. PubMed ID: 23062008
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of hnRNP A2/B1 inhibits cell proliferation, invasion and cell cycle triggering apoptosis in cervical cancer via PI3K/AKT signaling pathway.
Shi X; Ran L; Liu Y; Zhong SH; Zhou PP; Liao MX; Fang W
Oncol Rep; 2018 Mar; 39(3):939-950. PubMed ID: 29328485
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneous Nuclear Ribonucleoprotein A1 (hnRNP A1) and hnRNP A2 Inhibit Splicing to Human Papillomavirus 16 Splice Site SA409 through a UAG-Containing Sequence in the E7 Coding Region.
Zheng Y; Jönsson J; Hao C; Shoja Chaghervand S; Cui X; Kajitani N; Gong L; Wu C; Schwartz S
J Virol; 2020 Sep; 94(20):. PubMed ID: 32759322
[TBL] [Abstract][Full Text] [Related]
11. Splicing factor hnRNP A2/B1 regulates tumor suppressor gene splicing and is an oncogenic driver in glioblastoma.
Golan-Gerstl R; Cohen M; Shilo A; Suh SS; Bakàcs A; Coppola L; Karni R
Cancer Res; 2011 Jul; 71(13):4464-72. PubMed ID: 21586613
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneous nuclear ribonucleoproteins A1 and A2 modulate expression of Tid1 isoforms and EGFR signaling in non-small cell lung cancer.
Chen CY; Jan CI; Pi WC; Wang WL; Yang PC; Wang TH; Karni R; Wang TC
Oncotarget; 2016 Mar; 7(13):16760-72. PubMed ID: 26919236
[TBL] [Abstract][Full Text] [Related]
13. Dominant-negative antagonists of the Ras-ERK pathway: DA-Raf and its related proteins generated by alternative splicing of Raf.
Endo T
Exp Cell Res; 2020 Feb; 387(2):111775. PubMed ID: 31843497
[TBL] [Abstract][Full Text] [Related]
14. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
15. miR-4510 blocks hepatocellular carcinoma development through RAF1 targeting and RAS/RAF/MEK/ERK signalling inactivation.
Ghousein A; Mosca N; Cartier F; Charpentier J; Dupuy JW; Raymond AA; Bioulac-Sage P; Grosset CF
Liver Int; 2020 Jan; 40(1):240-251. PubMed ID: 31612616
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneous nuclear ribonucleoprotein A2/B1 in association with hTERT is a potential biomarker for hepatocellular carcinoma.
Mizuno H; Honda M; Shirasaki T; Yamashita T; Yamashita T; Mizukoshi E; Kaneko S
Liver Int; 2012 Aug; 32(7):1146-55. PubMed ID: 22372738
[TBL] [Abstract][Full Text] [Related]
17. HnRNP A1 controls a splicing regulatory circuit promoting mesenchymal-to-epithelial transition.
Bonomi S; di Matteo A; Buratti E; Cabianca DS; Baralle FE; Ghigna C; Biamonti G
Nucleic Acids Res; 2013 Oct; 41(18):8665-79. PubMed ID: 23863836
[TBL] [Abstract][Full Text] [Related]
18. PRMT6 Regulates RAS/RAF Binding and MEK/ERK-Mediated Cancer Stemness Activities in Hepatocellular Carcinoma through CRAF Methylation.
Chan LH; Zhou L; Ng KY; Wong TL; Lee TK; Sharma R; Loong JH; Ching YP; Yuan YF; Xie D; Lo CM; Man K; Artegiani B; Clevers H; Yan HH; Leung SY; Richard S; Guan XY; Huen MSY; Ma S
Cell Rep; 2018 Oct; 25(3):690-701.e8. PubMed ID: 30332648
[TBL] [Abstract][Full Text] [Related]
19. Loss of RDM1 enhances hepatocellular carcinoma progression via p53 and Ras/Raf/ERK pathways.
Chen SL; Liu LL; Wang CH; Lu SX; Yang X; He YF; Zhang CZ; Yun JP
Mol Oncol; 2020 Feb; 14(2):373-386. PubMed ID: 31670863
[TBL] [Abstract][Full Text] [Related]
20. Sirtuin-mediated deacetylation of hnRNP A1 suppresses glycolysis and growth in hepatocellular carcinoma.
Yang H; Zhu R; Zhao X; Liu L; Zhou Z; Zhao L; Liang B; Ma W; Zhao J; Liu J; Huang G
Oncogene; 2019 Jun; 38(25):4915-4931. PubMed ID: 30858544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
